PRESS RELEASE For immediate release QUÉBEC, Dec. 4, 2025 - Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescription drugs targeting fibroinflammatory...
Press Releases
Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member
Fourth quarter distribution revenues of $1.3 million Fourth quarter net loss of $0.4 million, $0.003 per share Annual distribution revenues of $23.6 million Annual net loss of $6 million, $0.041 per share Devonian is debt free with $7 million in cash as of July 31,...
Devonian Health Group Inc. announces its participation to the ThinkEquity Conference in New York and closing of a Non-Brokered Private Placement of Units
PRESS RELEASE For immediate release NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES QUEBEC, Oct. 22, 2025 - Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical...
Devonian Provides Corporate Update and Additional Information Regarding its Previously Announced Private Placement
PRESS RELEASE For immediate release Devonian Provides Corporate Update and Additional Information Regarding its Previously Announced Private Placement QUEBEC, August 22, 2025 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a...
Devonian Announces Closing of a Private Placement of Units
PRESS RELEASE For immediate release Devonian Announces Closing of a Private Placement of Units Not for distribution to United States newswire services or for dissemination in the United States QUEBEC, August 7, 2025 – Devonian Health Group Inc. (“Devonian” or the...
Devonian Health Group Reports Third Quarter 2025 Financial Results
PRESS RELEASE For immediate release Devonian Health Group Reports Third Quarter 2025 Financial Results Third quarter revenues increased 36% compared to 3Q24 Third quarter net loss of $0.032 per share Québec, QUÉBEC, June 26, 2025 – Devonian Health Group Inc....
DEVONIAN APPOINTS NEW OFFICERS AND ANNOUNCES GRANT OF STOCK OPTIONS
PRESS RELEASE For immediate release QUÉBEC, Québec, June 9, 2025 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced the...
Devonian Health Group Announces Reinstatement of Quotation on the TSXV
PRESS RELEASE For immediate release QUÉBEC, April 28, 2025 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), announced that the TSX Venture Exchange (the “Exchange”) has approved its application for reinstatement of trading of the...
Devonian Health Group Reports Second Quarter 2025 Financial Results
PRESS RELEASE For immediate release Second quarter revenue increased 275% year over year Second quarter net loss of $0.001 per share Debt repaid in full Québec, QUÉBEC, April 15, 2025 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB:...
Devonian Health Group Reports Cease Trade Order
PRESS RELEASE For immediate release QUEBEC CITY--(BUSINESS WIRE)--April 14, 2025--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), announces that the Autorité des Marchés Financiers (the “AMF”) has issued a failure to file cease...